中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页
机构
成果
学者
登录
注册
登陆
×
验证码:
换一张
忘记密码?
记住我
×
校外用户登录
CAS IR Grid
机构
上海药物研究所 [32]
上海硅酸盐研究所 [10]
过程工程研究所 [5]
大连化学物理研究所 [2]
深圳先进技术研究院 [1]
高能物理研究所 [1]
更多
采集方式
OAI收割 [51]
iSwitch采集 [2]
内容类型
期刊论文 [52]
学位论文 [1]
发表日期
2024 [1]
2023 [6]
2022 [7]
2021 [7]
2020 [7]
2019 [6]
更多
学科主题
Biochemist... [1]
Chemistry,... [1]
Engineerin... [1]
Materials ... [1]
Polymer Sc... [1]
筛选
浏览/检索结果:
共53条,第1-10条
帮助
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
提交时间升序
提交时间降序
发表日期升序
发表日期降序
题名升序
题名降序
作者升序
作者降序
Targeting JMJD1C to selectively disrupt tumor T
reg
cell fitness enhances antitumor immunity
期刊论文
OAI收割
NATURE IMMUNOLOGY, 2024, 页码: 32
作者:
Long, Xuehui
;
Zhang, Sulin
;
Wang, Yuliang
;
Chen, Jingjing
;
Lu, Yanlai
  |  
收藏
  |  
浏览/下载:17/0
  |  
提交时间:2024/03/25
Breaking Tumor Immunosuppressive Network by Regulating Multiple Nodes with Triadic Drug Delivery Nanoparticles
期刊论文
OAI收割
ACS NANO, 2023, 卷号: 17, 期号: 18, 页码: 17826-17844
作者:
Yan, Wenlu
;
Li, Yu
;
Zou, Yiting
;
Zhu, Runqi
;
Wu, Ting
  |  
收藏
  |  
浏览/下载:8/0
  |  
提交时间:2023/12/08
triple-negative breast cancer
antitumor immunity
tumor-associated macrophages
myeloid-derived suppressorcells
immune network
nanoparticle
Nanovesicles loaded with a TGF-& beta; receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy
期刊论文
OAI收割
NATURE COMMUNICATIONS, 2023, 卷号: 14, 期号: 1, 页码: 18
作者:
Zhou, Mengxue
;
Wang, Jiaxin
;
Pan, Jiaxing
;
Wang, Hui
;
Huang, Lujia
  |  
收藏
  |  
浏览/下载:11/0
  |  
提交时间:2023/10/17
Targeting lactate metabolism and immune interaction in breast tumor via protease-triggered delivery
期刊论文
OAI收割
JOURNAL OF CONTROLLED RELEASE, 2023, 卷号: 358, 页码: 706-717
作者:
Zhao, Pengfei
;
Wang, Shuang
;
Jiang, Jizong
;
Gao, Yanrong
;
Wang, Yuewei
  |  
收藏
  |  
浏览/下载:12/0
  |  
提交时间:2023/10/17
Legumain
Lactate
Tumor immune microenvironment (TIME)
Quercetin
Immunometabolism
Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1-Independent Manner
期刊论文
OAI收割
CANCER IMMUNOLOGY RESEARCH, 2023, 卷号: 11, 期号: 2, 页码: 241-260
作者:
Long, Yiru
;
Chen, Runqiu
;
Yu, Xiaolu
;
Tong, Yongliang
;
Peng, Xionghua
  |  
收藏
  |  
浏览/下载:1/0
  |  
提交时间:2024/03/27
Enhanced glypican-3-targeted identification of hepatocellular carcinoma with liver fibrosis by pre-degrading excess fibrotic collagen
期刊论文
OAI收割
Acta Biomaterialia, 2023, 卷号: 158, 页码: 435- 448
作者:
Zhuo, Jiaming
;
Wang, Yueqi
;
Hui, Hui
;
Li, Changjian
;
Yang, Junying
  |  
收藏
  |  
浏览/下载:13/0
  |  
提交时间:2023/05/04
Recombinant cell-penetrating trichosanthin synergizes anti-PD-1 therapy in colorectal tumor
期刊论文
OAI收割
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2023, 卷号: 19, 期号: 6, 页码: 1698-1712
作者:
Zhang, Meng
;
Liu, Ergang
;
Chen, Guihua
;
Tang, Yisi
  |  
收藏
  |  
浏览/下载:7/0
  |  
提交时间:2023/10/17
Trichosanthin
cell -penetrating peptide
anti -PD-1 therapy
tumor immune microenvironment
colorectal cancer
Cyclic enhancement of hypoxic microenvironment via an intelligent nanoamplifier for activated NIR-II fluorescence/photoacoustic imaging-guided precise synergistic therapy
期刊论文
OAI收割
MATERIALS TODAY BIO, 2022, 卷号: 17, 页码: 10
作者:
  |  
收藏
  |  
浏览/下载:16/0
  |  
提交时间:2023/04/10
Second near -infrared window
Dual -modal imaging
Activatable NIR-II FL Imaging
Tumor hypoxia
Synergistic tumor therapy
In-situ clickable prodrug nanoplatform locally activates T lymphocytes to potentiate cancer immunotherapy
期刊论文
OAI收割
NANO TODAY, 2022, 卷号: 47, 页码: 11
作者:
Hou, Bo
;
Ye, Jiayi
;
Li, Junhao
;
Xu, Zhiai
;
Yu, Haijun
  |  
收藏
  |  
浏览/下载:29/0
  |  
提交时间:2023/04/10
Immune-excluded tumor
Extracellular matrix
In-situ click reaction
Prodrug nanoparticles
Immune resistance
PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way
期刊论文
OAI收割
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 卷号: 10, 期号: 10, 页码: 15
作者:
Yu, Xiaolu
;
Long, Yiru
;
Chen, Binfan
;
Tong, Yongliang
;
Shan, Mengwen
  |  
收藏
  |  
浏览/下载:35/0
  |  
提交时间:2022/12/13
PD-L1
TLR7
nanobody-drug-conjugate
cancer immunotherapy